<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03410732</url>
  </required_header>
  <id_info>
    <org_study_id>LAUDC 2017001</org_study_id>
    <nct_id>NCT03410732</nct_id>
  </id_info>
  <brief_title>Dendritic Cell-based Immunotherapy in Treatment Gastric Cancer</brief_title>
  <official_title>Activated Autologous Dendritic Cells by Autologous Tumor Cell Membrane Proteins in Treatment of Gastric Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>LanZhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>LanZhou University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Study objectives are to investigate the efficacy and safety of activated autologous dendritic&#xD;
      cells (DCs) in treatment of gastric cancer. DCs are activated by the proteins from autologous&#xD;
      tumor cell membrane and cytokines in vitro. The efficacy endpoints include objective&#xD;
      response, immune-cell response, recurrent rate after a radical surgery, progression-free&#xD;
      survival and overall survival, and the safety endpoints include adverse events, laboratory&#xD;
      tests, ECG, ECOG-PT, etc.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study objectives are to investigate the efficacy and safety of activated autologous dendritic&#xD;
      cells (DCs) in treatment of gastric cancer. The autologous DCs are collected and enriched&#xD;
      from peripheral blood, and then are activated by the proteins from autologous tumor cell&#xD;
      membrane and cytokines in vitro. The efficacy endpoints include objective response,&#xD;
      immune-cell response, recurrent rate after a radical surgery, progression-free survival and&#xD;
      overall survival, and the safety endpoints include adverse events, laboratory tests, ECG,&#xD;
      ECOG-PT, etc. All patients will be followed up for at least 2 years after treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">December 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression-free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Time to progression/death or censored time</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>recurrent rate</measure>
    <time_frame>3 years</time_frame>
    <description>the rate of cancer recurring after surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival rate</measure>
    <time_frame>5 years</time_frame>
    <description>time to death or censored time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>immune-cells response</measure>
    <time_frame>3 months</time_frame>
    <description>CD4/CD8 T lymphocyte percentage change</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse event rate</measure>
    <time_frame>3 months</time_frame>
    <description>Adverse event rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Gastric Cancer</condition>
  <arm_group>
    <arm_group_label>Radical surgery plus activated DCs</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>In 21 days after a radical surgery, activated DCs are iv infused</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radical surgery only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radical surgery only group as a control group</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>activated DCs</intervention_name>
    <description>autologous dendritic cells are collected and enriched from 50 ml of peripheral blood, then activated by autologous tumor cell membrane proteins. Then the activated DCs are iv infused in 21 days after a radical surgery.</description>
    <arm_group_label>Radical surgery plus activated DCs</arm_group_label>
    <other_name>activated DCs by autologous tumor cell membrane proteins</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical surgery only</intervention_name>
    <description>Only radical surgery is given to the control group</description>
    <arm_group_label>Radical surgery only</arm_group_label>
    <arm_group_label>Radical surgery plus activated DCs</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent given before any trial-specific procedure is initiated&#xD;
&#xD;
          2. Male or female, at least 18 years of age at the time of informed consent&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1&#xD;
&#xD;
          4. Life expectancy &gt;3 months assessed during Screening&#xD;
&#xD;
          5. Documented (histologically- or cytologically-proven) gastric cancer that is can be&#xD;
             radially removed&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Non-healing wounds on any part of the body&#xD;
&#xD;
          2. Active thrombosis, or a history of deep vein thrombosis or pulmonary embolism, within&#xD;
             1 month prior to surgery, unless adequately treated and stable&#xD;
&#xD;
          3. Active uncontrolled bleeding or a known bleeding diathesis&#xD;
&#xD;
          4. Significant cardiovascular disease or condition, including:&#xD;
&#xD;
               1. Congestive heart failure currently requiring therapy&#xD;
&#xD;
               2. Class III or IV cardiovascular disease according to the New York Heart&#xD;
                  Association's (NYHA) functional criteria (25)&#xD;
&#xD;
               3. Need for antiarrhythmic medical therapy for a ventricular arrhythmia&#xD;
&#xD;
               4. Severe conduction disturbance (e.g., 3rd degree heart block)&#xD;
&#xD;
               5. Unstable angina pectoris (last episode at least 6 months prior to surgery)&#xD;
&#xD;
               6. Uncontrolled hypertension (per the Investigator's discretion)&#xD;
&#xD;
               7. Myocardial infarction within 6 months prior to C1/D1&#xD;
&#xD;
          5. Abnormal hematologic, renal or hepatic function as defined by the following criteria:&#xD;
&#xD;
               1. Absolute neutrophil count (ANC) &lt;1.5 ×109/L (1500/mm3)&#xD;
&#xD;
               2. Hemoglobin ≤9 g/dL&#xD;
&#xD;
               3. Platelet count &lt;75 ×109/L (75,000/mm3)&#xD;
&#xD;
               4. Serum creatinine &gt;1.5 × upper limit of normal (ULN) for the institution&#xD;
&#xD;
               5. Aspartate aminotransferase (AST) &gt;3.5 × ULN for the institution or AST &gt;5 × ULN&#xD;
                  for the institution in case of known liver metastases&#xD;
&#xD;
               6. Alanine aminotransferase (ALT) &gt;3.5 × ULN for the institution or ALT &gt;5 × ULN for&#xD;
                  the institution in case of known liver metastases&#xD;
&#xD;
               7. Total bilirubin &gt;1.5 × ULN for the institution&#xD;
&#xD;
               8. Prothrombin time as assessed by International Normalized Ratio (INR) &gt;1.5 × ULN&#xD;
                  for the institution*&#xD;
&#xD;
               9. Partial thromboplastin time (PTT) &gt;1.5 × ULN for the institution*&#xD;
&#xD;
          6. Any of the following within 2 weeks prior to surgery:&#xD;
&#xD;
               1. Any serious or uncontrolled infection&#xD;
&#xD;
               2. Any infection requiring parenteral antibiotics&#xD;
&#xD;
               3. Unexplained fever &gt;38.0 °C&#xD;
&#xD;
          7. Any other life-threatening illness, significant organ system dysfunction, or&#xD;
             clinically significant laboratory abnormality, which in the opinion of the&#xD;
             Investigator, would either compromise the patient's safety or interfere with the&#xD;
             evaluation of the safety of the trial treatment&#xD;
&#xD;
          8. Any kind of disorder that compromises the ability of the patient to give written&#xD;
             informed consent and/or to comply with trial procedures or is unwilling or unable to&#xD;
             comply with trial requirements at the discretion of the Investigator&#xD;
&#xD;
          9. Breast feeding, or plans by the patient (or the patient's partner) to become pregnant&#xD;
             during treatment or within 4 months after the end of treatment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yumin Li</last_name>
    <role>Principal Investigator</role>
    <affiliation>LanZhou University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yumin Li, MD, PhD</last_name>
    <phone>+8613893615421</phone>
    <email>liym@lzu.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gui Gao, MD, PhD</last_name>
    <phone>+86-931-8942281</phone>
    <email>Scottgao1110@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Lanzhou University Second Hospital</name>
      <address>
        <city>Lanzhou</city>
        <state>Gansu</state>
        <zip>730030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumin Li, MD, PhD</last_name>
      <phone>+8613893615421</phone>
      <email>liym@lzu.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>January 16, 2018</study_first_submitted>
  <study_first_submitted_qc>January 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2018</study_first_posted>
  <last_update_submitted>January 24, 2018</last_update_submitted>
  <last_update_submitted_qc>January 24, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>LanZhou University</investigator_affiliation>
    <investigator_full_name>Gui Gao, Ph D, MD</investigator_full_name>
    <investigator_title>MD, Ph D</investigator_title>
  </responsible_party>
  <keyword>dendritic cell</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>tumor cell membrane proteins</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stomach Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>we'll update the registration system. But final data will be summarized and published in a medical journal</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

